跳转到主要内容

Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

中华医学杂志(英文版) 2026 年第 139 卷第 4 期 589-596 页

DOI:10.1097/CM9.0000000000003649

20

作者人数

1

被引次数

来源:Crossref,截至 2026-10-20

作者

  1. 1
    Wenting Chen 第一作者
  2. 2
    Jianhua You
  3. 3
    Li’e Lin
  4. 4
    Xiaojing Yan
  5. 5
    Gang An
  6. 6
    Yafei Wang
  7. 7
    Weiwei Tian
  8. 8
    Kaiyang Ding
  9. 9
    Xi Zhang
  10. 10
    Wenming Chen

    首都医科大学附属北京朝阳医院

  11. 11
    Yingxue Wang
  12. 12
    Baijun Fang
  13. 13
    Jing Liu

    中南大学湘雅三医院

  14. 14
    Weilin Xia
  15. 15
    Zhaoyi Feng
  16. 16
    Lei Zhou
  17. 17
    Zhini Wang
  18. 18
    Dan Shen
  19. 19
    Gang Liu
  20. 20
    Weili Zhao

参考文献 共 31 条

  1. 1 Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study 10.1038/leu.2011.196
  2. 2 Management of multiple myeloma in the newly diagnosed patient 10.1182/asheducation-2017.1.498
  3. 3 Current frontline treatment of multiple myeloma
  4. 4 Bortezomib-based regimens for newly diagnosed multiple myeloma in China: A report of 12-year real-world data 10.3389/fphar.2020.561601
  5. 5 Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China 10.1002/cam4.5234
  6. 6 The changing landscape of relapsed and/or refractory multiple myeloma (MM): Fundamentals and controversies 10.1186/s40364-021-00344-2
  7. 7 Management of multiple myeloma in the relapsed/refractory patient 10.1182/asheducation-2017.1.508
  8. 8 Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma 10.1016/j.clml.2022.01.011
  9. 9 Daratumumab: A review in relapsed and/or refractory multiple myeloma 10.1007/s40265-017-0837-7
  10. 10 Isatuximab: First approval 10.1007/s40265-020-01311-1
  11. 11 SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies 10.1158/1078-0432.ccr-14-0695
  12. 12 Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma 10.1158/1078-0432.ccr-16-3192
  13. 13 Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study 10.1016/s0140-6736(19)32556-5
  14. 14 Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study 10.1016/s1470-2045(22)00019-5
  15. 15 Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
  16. 16 Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in east asian patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis 10.1016/j.clml.2022.04.005
  17. 17 Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: Results of a UK-wide real-world dataset 10.1097/hs9.0000000000000738
  18. 18 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study 10.1111/ejh.14225
  19. 19 A Bayesian approach for inference from a bridging study with binary outcomes 10.1080/10543406.2012.698436
  20. 20 Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study 10.1186/s13045-017-0501-4
  21. 21 A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China 10.1007/s12185-020-03044-z
  22. 22 Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies 10.1002/sim.6607
  23. 23 Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial 10.1186/s12885-022-09802-y
  24. 24 Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: A multicenter, open-label, single-arm trial 10.1007/s00277-023-05558-y
  25. 25 Pomalidomide and dexamethasone are effective in relapsed or refractory multiple myeloma in a real-life setting: A multicenter retrospective study in Taiwan 10.3389/fonc.2021.695410
  26. 26 Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China 10.1002/cam4.7232
  27. 27 Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): Extended follow up of an open-label, randomised, multicentre, phase 3 trial 10.1016/s2352-3026(23)00218-1
  28. 28 Prevalence and incidence of multiple myeloma in urban area in China: A national population-based analysis 10.3389/fonc.2019.01513
  29. 29 Real-world Data on the efficacy and safety of ixazomib-based therapy in multiple myeloma: A single-center study in China 10.2147/cmar.s261887
  30. 30 The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China (in Chinese)
  31. 31 A retrospective study of the BiRd regimen in the treatment of relapsed/ refractory multiple myeloma (in Chinese)

数据来源

论文信息:
中华医学期刊网、Crossref
作者名单:
Crossref
被引次数:
Crossref,截至 2026-10-20
参考文献:
Crossref

论文的著作权归作者与出版方所有,本站只整理公开的题录信息并附原文链接,不构成任何医疗建议。